OCULAR SURFACE ACADEMY: Recent Episodes
OCULAR SURFACE ACADEMY
Innovation in dry eye disease diagnostics and therapeutics has increased dramatically in the last few years. Join Scott Schachter, OD, and Christopher Starr, MD, as they meet with the researchers behind each committee of the global dry eye consensus, TFOS DEWS II. Optometrists and ophthalmologists who want to start or ramp up their dry eye practice should tune in and subscribe, as each episode will feature clinical takeaways.
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. In the last episode, Dr. Sullivan and Amy Gallant Sullivan discuss the next workshop […]
Dr. Schachter speaks with Azura Ophthalmics CEO Marc Gleeson about the company’s pipeline, which is focused on the development of ophthalmic keratolytics for the treatment of disorders affecting the lid margin and ocular surface. The novel approach targets hyperkeratinization and impaired lipid secretory function of […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. In this penultimate episode of the series, Dr. Sullivan and Amy Gallant Sullivan provide […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. In the diagnostic methodology episode, Dr. Wolffsohn explains the complexities involved in selecting specific […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. In part 2 of the pain and sensation episode, Drs Galor and Hamrah talk […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. In part 1 of this two part episode on pain and sensation, Drs. Galor […]
Dr. Markouli explains that the goal of the pathophysiology committee was first, to understand the normal, healthy, ocular surface and adnexa before discussing the changes that occur in dry eye disease. A key point to come out of the pathophysiology workshop, she notes, is that […]
Robert S. Herrick, MD, a corneal external disease specialist, cofounded Lacrimedics in 1983 and has developed many innovative products and procedures for dry eye disease. In this Industry Spotlight he discusses his journey to a greater understanding of lacrimal system dysfunction, the benefits of occlusion therapy, and the development of […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. Drs Jones and Deng talk about the importance of clinical evidence to drive proper […]
Glen Curran, Vice President, Marketing, US Eyecare at Allergan discusses the merger with Abbvie and what it was like to go through the transition during the pandemic. He notes how smooth the process was and what Abbvie brings to the table: a focus on science […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. Dr. Gupta talks about where the ASCRS clinical algorithm fits in with TFOS DEWS […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com What innovations with regard to cataract and refractive surgery have been developed to reduce […]
Founder Amy Gallant Sullivan discusses “toxic beauty,” the correlation between cosmetic usage and dry eye. Two decades of entrenchment in the ocular surface space have culminated in the formation of Boston-based biobeauty startup ÈSSIRI Labs, the creators of ÈYES ARE THE STORY Optocosmetics. Amy is […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. Do you consider the neurosensory component of the lacrimal functional unit? Eye care specialists […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. Do you know what is in a tear? Dr. Wilcox discusses the role of […]
Sonja Krösser, PhD, Novaliq’s Head of Clinical Development, discusses research around the late-stage compounds NOV03 and CyclASol. The former being developed to treat evaporative DED associated with meibomian gland dysfunction. CyclASol, ophthalmic solution of 0.1% cyclosporine A in EyeSol, is an anti-inflammatory and immunomodulating drug […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. Are you using a validated questionnaire? Dr. Stapleton offers insight on the importance of […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. Does sex affect dry eye? In the Sex, Gender, and Hormone episode, Dr. Sullivan […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. In part 2 of the Definition and Classification episode, Drs. Craig and Nichols discuss […]
TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. Dry eye was first defined as a disease—not just a syndrome—in 1995. In part […]
Find out more about Regener-Eyes® first in class biologic eye drop with anti-inflammatory cytokines and growth factors, with the manufacturer’s Founder, Chairman, and CEO C. Randall Harrell, MD. The drop is made with the company’s d-MAPPS™ (derived–Multiple Allogeneic Proteins Paracrine Signaling) platform technology engineered to stimulate […]
Words matter! In this episode, Drs. Craig and Nelson describe the hurdles TFOS faced in arriving at the definition and the classification of dry eye disease. The group understood that revising the definition would require extremely care as it was to set the tone for […]
Dr. Sullivan returns for Part 2 of the History of TFOS. Here he discusses embarking on the work that would become TFOS DEWS 2, the International Workshop on Meibomian Gland Dysfunction, and current research on the adverse ocular effects of many of the ingredients commonly […]
Part 1 of this 2-part episode offers a rare peek behind the curtain with David Sullivan, MD, of Schepens Eye Research Institute and Harvard Medical School. Dr. Sullivan is the Founder, recent President, and current Chairman of the Board of Directors of the Tear Film […]